Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellICCC -8.45%55 EV-to-FCF is 30.52 as of Jul. 16, 2026. GuruFocus rates ICCC with a GF Score™ of 55/100 and a GF Value™ of $6.86 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 336 Biotechnology companies, ImmuCell ranks worse than 68.45% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ImmuCell's Enterprise Value is $103.04 Mil.
ImmuCell's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $3.38 Mil. Therefore, ImmuCell's EV-to-FCF for today is 30.52.
The historical rank and industry rank for ImmuCell's EV-to-FCF or its related term are showing as below:
ICCC'
s EV-to-FCF Range Over the Past 10 Years
Min: -571.08 Med: -14.87 Max: 99.62
Current: 30.52
During the past 13 years, the highest EV-to-FCF of ImmuCell was 99.62. The lowest was -571.08. And the median was -14.87.
ICCC's EV-to-FCF is ranked worse than 68.45% of 336
companies
in the Biotechnology industry
Industry Median: 15.32
vs ICCC: 30.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ImmuCell's share price for today is $10.72.
ImmuCell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ImmuCell EV-to-FCF Related Terms
ImmuCell EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ImmuCell's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ImmuCell's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ImmuCell's EV-to-FCF falls into.
ImmuCell's current Enterprise Value is $103.04 Mil.
ImmuCell's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuCell (ICCC) has a EV-to-FCF of 30.52 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ImmuCell and its competitors. According to the industry distribution chart, ImmuCell ranks #230 out of 336 companies in the Biotechnology industry, placing it in the top 68.5%.
Is ImmuCell's EV-to-FCF too high?
ImmuCell's current EV-to-FCF is 30.52. The Biotechnology industry median EV-to-FCF is 15.32. ImmuCell's value of 30.52 is 99.2% above this industry median. Based on the distribution chart, ImmuCell ranks #230 out of 336 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ImmuCell has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's EV-to-FCF compare to LONA and PYPD?
According to the Biotechnology industry distribution chart, ImmuCell ranks #230 out of 336 companies for EV-to-FCF. This places ImmuCell in the lower half of its industry. The industry median EV-to-FCF is 15.32. ImmuCell's value of 30.52 is 99.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.32, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuCell's current EV-to-FCF of 30.52 is 99.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ImmuCell and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuCell's current EV-to-FCF is 30.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.86, compared to a current price of $10.72 — trading 56.3% above its estimated fair value. The current EV-to-FCF is 30.52 and 99.2% above the Biotechnology industry median of 15.32. ImmuCell's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ImmuCell (ICCC), the current EV-to-FCF is 30.52 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (ICCC) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of $10.72 is trading 56.3% above its estimated GF Value™ of $6.86.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for ICCC:
EV-to-FCF: 30.52
GF Value™: $6.86 vs. price of $10.72 (56.3% above fair value)
Industry Position: 99.2% above the Biotechnology median (#230 of 336)
No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
55GF Score
Get the complete analysis for ICCC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCC has been successfully added to your 
